Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients

OBJECTIVE: The efficacy of tocilizumab (TCZ) in GCA is supported by two randomized controlled studies, in which TCZ allowed remission to be achieved after 52 weeks of treatment. However, after discontinuation of treatment, half of the patients relapsed. The aim of this study was to analyse the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Regola, Francesca, Cerudelli, Elisabetta, Bosio, Giovanni, Andreoli, Laura, Tincani, Angela, Franceschini, Franco, Toniati, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359771/
https://www.ncbi.nlm.nih.gov/pubmed/32685912
http://dx.doi.org/10.1093/rap/rkaa017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359771/
https://www.ncbi.nlm.nih.gov/pubmed/32685912
http://dx.doi.org/10.1093/rap/rkaa017

Ejemplares similares